anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (preservative free)

AdipoGen Life Sciences

anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (preservative free)

10

Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain.

Neutralisation/Blocking

Research Use Only

Monoclonal

D1(A12)

1 mg/ml

>95%

ADAM17

ADAM metallopeptidase domain 17

a disintegrin and metalloproteinase 17; ADAM metallopeptidase domain 18; ADAM18; cartilage snake venom-like protease; CD156B; CSVP; disintegrin and metalloproteinase domain-containing protein 17; NISBD; NISBD1; snake venom-like protease; TACE; TNF-alpha convertase; TNF-alpha convertase enzyme; TNF-alpha converting enzyme; tumor necrosis factor, alpha, converting enzyme

Human

IgG1

ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer. - Recombinant Antibody. Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain. Species cross-reactivity: Human. Clone: D1(A12). Isotype: Human IgG1. Applications: FUNC (Blocking). Host: E. coli. Liquid. In PBS. ADAM17 (Disintegrin and metalloproteinase domain-containing protein 17), also called TACE (Tumor necrosis factor-alpha-converting enzyme) is the prototype of the ADAM family of ectodomain shedding proteases (sheddase). ADAM17 is understood to be involved in the processing of TNF-alpha at the surface of the cell and from within the intracellular membranes of the trans-Golgi network. This process involves the cleavage and release of a soluble ectodomain from membrane-bound pro-proteins (such as pro-TNF-alpha) and is of known physiological importance. ADAM17 is responsible for the processing of a diverse variety of membrane-anchored cytokines, cell adhesion molecules, receptors, ligands and enzymes, including cleaving epidermal growth factor receptor (EGFR) ligands and extracellular Notch1. The proteolytic cleavage is an indispensable activation event for many of these substrates, ADAM17 has emerged as an attractive therapeutic target for the treatment of inflammatory diseases (e.g. rheumatoid arthritis) or inflammation associated cancer.

Human

2°C to 8°C,-20°C

12352203